Publications

diabetes (11 POSTS)

2022 (1 POST)

Diabetes specific ONS led to a blunted postprandial glucose response and a 26% reduction in peak blood glucose levels compared to a standard ONS

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Torres KA. Diabetes specific ONS led to a blunted postprandial glucose response and a 26% reduction in peak blood glucose levels compared to a standard ONS. Presented at FNCE 2022 Food & Nutrition Conference & Expo, Orlando, FL, October 2022.

2021 (1 POST)

Effect of diabetes-specific oral nutritional supplements on postprandial glycemic response in adults with type 2 diabetes mellitus

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Araujo Torres K. 2021. Effect of diabetes-specific oral nutritional supplements on postprandial glycemic response in adults with type 2 diabetes mellitus. Poster presented at ASPEN Nutrition Science & Practice Conference, March 2021.

2019 (1 POST)

Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study

Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks NC, Cyr PL, Taylor S. 2019. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study. Clin Therapeut 41(2):303–313; doi: 10.1016/j.clinthera.2018.12.014.

View Abstract

2018 (2 POSTS)

Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.

Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy. ISPOR 23rd Annual Conference, Baltimore MD, 2018.

2017 (1 POST)

The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older

Sacks NC, Liu Y, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J… Cyr PL, et al. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. American Heart Association Scientific Sessions, Anaheim CA, 2017.

2016 (2 POSTS)

Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

View Abstract

Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, … Dingley KH, et al. 2016. Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7 (12):1107–1111; doi: 10.1021/acsmedchemlett.6b00314. PMID: 27994747.

View Abstract

2015 (1 POST)

Design of potent and orally active GPR119 agonists for the treatment of type II diabetes

Liu P, Hu Z, DuBois BG, Moyes CR, Hunter DN, Zhu C, … Dingley KH, et al. 2015. Design of potent and orally active GPR119 agonists for the treatment of type II diabetes. ACS Med Chem Lett 6(8):936–941; doi: 10.1021/acsmedchemlett.5b00207. PMID: 26288697.

View Abstract

2013 (1 POST)

Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice

Karchapati L, Bednar KJ, Adams DE, Wu Y, Mitter RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. 2013. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 47:94–103.

View Abstract

2006 (1 POST)

Are dioxin body burdens surrogates for other risk factors in associations between dioxin and diabetes?

Haws LC, Scott PK, Unice KM, Gough M, Harris MA, Staskal DF, Paustenbach DJ, Pavuk M. Are dioxin body burdens surrogates for other risk factors in associations between dioxin and diabetes? Dioxin 2006, Oslo, Norway, August 2006.